EnglishFrenchGermanItalianSpanish

WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

Ann Arbor, MI and Salt Lake City, UT (April, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, and XCR Diagnostics, a sample-to-result systems company focused on actionable near patient results in 10 minutes or less, have announced today a chemistry license partnership to develop and implement three XCR® assays...

NeuMoDx™ Announces Completion of Series B Financing Funds Product Development for High Throughput Molecular Diagnostic Platform Ann Arbor, Michigan (March 26, 2014) – NeuMoDx™ Molecular, Inc., a privately held diagnostics company developing a new platform for high throughput, low cost molecular testing, today announced completion of its Series B financing. Pfizer Ventures led the $21 million...

Ann Arbor, Michigan (July 2018) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it has received FDA 510(k) clearance for its NeuMoDx™ 288 Molecular System and its NeuMoDx™ GBS Assay. The fully automated NeuMoDx™ 288 Molecular System is the first offering in a family of scalable platforms that integrate...

QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx™ to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs Hilden, Germany, and Ann Arbor, Michigan, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx™ Molecular, Inc. today announced a strategic partnership to...